115195
论文已发表
注册即可获取德孚的最新动态
IF 收录期刊
- 3.6 Breast Cancer (Dove Med Press)
- 4.3 Clin Epidemiol
- 2.6 Cancer Manag Res
- 3.2 Infect Drug Resist
- 4.1 Clin Interv Aging
- 6.1 Drug Des Dev Ther
- 4.1 Int J Chronic Obstr
- 8.7 Int J Nanomed
- 2.5 Int J Women's Health
- 3.2 Neuropsych Dis Treat
- 2.4 OncoTargets Ther
- 2.6 Patient Prefer Adher
- 2.6 Ther Clin Risk Manag
- 3.1 J Pain Res
- 3.5 Diabet Metab Synd Ob
- 4.5 Psychol Res Behav Ma
- 3.4 Nat Sci Sleep
- 2.4 Pharmgenomics Pers Med
- 2.6 Risk Manag Healthc Policy
- 4.6 J Inflamm Res
- 2.3 Int J Gen Med
- 3.9 J Hepatocell Carcinoma
- 3.3 J Asthma Allergy
- 2.5 Clin Cosmet Investig Dermatol
- 3.0 J Multidiscip Healthc
已发表论文
舒巴坦-杜洛巴坦成功治疗重症急性胰腺炎合并多部位广泛耐药鲍曼不动杆菌感染：病例报告
Authors Ge Z , Li L, Wang L, Liu D, Liu Y
Received 23 October 2025
Accepted for publication 6 January 2026
Published 10 January 2026 Volume 2026:19 575394
DOI https://doi.org/10.2147/IDR.S575394
Checked for plagiarism Yes
Review by Single anonymous peer review
Peer reviewer comments 2
Editor who approved publication: Prof. Dr. Héctor Mora-Montes
Zhengmao Ge, Li Li, Longxin Wang, Dengke Liu, Yupeng Liu
Department of Critical Care Medicine, The 967 Hospital, Joint Logistics Support Force of PLA, Dalian, 116021, People’s Republic of China
Correspondence: Yupeng Liu, Department of Critical Care Medicine, The 967 Hospital, Joint Logistics Support Force of PLA, No. 80 Shengli Road, Dalian, Liaoning, 116021, People’s Republic of China, Email dalianicu@foxmail.com
Background: The management of severe acute pancreatitis (SAP) complicated by multi-site infections with extensively drug-resistant Acinetobacter baumannii (XDR-AB) represents a critical therapeutic challenge. This report describes, to our knowledge, an early successful application of sulbactam-durlobactam in an SAP patient with concurrent XDR-AB infections in the abdomen, biliary tract and lungs.
Case Presentation: A 36-year-old female with hypertriglyceridemic SAP developed infections at multiple sites, with cultures consistently yielding XDR-AB. After the failure of multiple last-line antimicrobial regimens, therapy was switched to sulbactam-durlobactam combined with meropenem. This change was followed by a substantial clinical improvement: body temperature normalized, infection biomarkers decreased significantly and microbiological clearance of XDR-AB from all sites was achieved, leading to successful liberation from mechanical ventilation and discharge from the ICU.
Conclusion: This case demonstrates that sulbactam-durlobactam can be a highly effective therapeutic option for achieving both clinical and microbiological cure in complex SAP cases with multi-site XDR-AB infections that are refractory to conventional treatment regimens. It contributes early real-world evidence supporting a new therapeutic strategy for managing such life-threatening, complex infections.
Keywords: severe acute pancreatitis, Acinetobacter baumannii, drug resistance, sulbactam-durlobactam, case report
Department of Critical Care Medicine, The 967 Hospital, Joint Logistics Support Force of PLA, Dalian, 116021, People’s Republic of China
Correspondence: Yupeng Liu, Department of Critical Care Medicine, The 967 Hospital, Joint Logistics Support Force of PLA, No. 80 Shengli Road, Dalian, Liaoning, 116021, People’s Republic of China, Email dalianicu@foxmail.com
Background: The management of severe acute pancreatitis (SAP) complicated by multi-site infections with extensively drug-resistant Acinetobacter baumannii (XDR-AB) represents a critical therapeutic challenge. This report describes, to our knowledge, an early successful application of sulbactam-durlobactam in an SAP patient with concurrent XDR-AB infections in the abdomen, biliary tract and lungs.
Case Presentation: A 36-year-old female with hypertriglyceridemic SAP developed infections at multiple sites, with cultures consistently yielding XDR-AB. After the failure of multiple last-line antimicrobial regimens, therapy was switched to sulbactam-durlobactam combined with meropenem. This change was followed by a substantial clinical improvement: body temperature normalized, infection biomarkers decreased significantly and microbiological clearance of XDR-AB from all sites was achieved, leading to successful liberation from mechanical ventilation and discharge from the ICU.
Conclusion: This case demonstrates that sulbactam-durlobactam can be a highly effective therapeutic option for achieving both clinical and microbiological cure in complex SAP cases with multi-site XDR-AB infections that are refractory to conventional treatment regimens. It contributes early real-world evidence supporting a new therapeutic strategy for managing such life-threatening, complex infections.
Keywords: severe acute pancreatitis, Acinetobacter baumannii, drug resistance, sulbactam-durlobactam, case report